KLOW Blend Research: BPC-157, GHK-Cu, TB-500 & KPV QC

KLOW peptide blend is a declared four-component dry research mixture — nominal BPC-157 10 mg, GHK-Cu 50 mg, TB-500 10 mg and KPV 10 mg (arithmetic label total 80 mg) — used for controlled analytical and cell-model studies of peptide mixtures; it has no single molecular formula because the ingredients are chemically distinct molecules, and no component-level literature automatically proves blend synergy (KLOW product page, verified 2026). This guide maps each declared component to a reference identity and published preclinical evidence, lists the QC questions a four-component blend raises, distinguishes KLOW from the three-component GLOW blend, and frames compliant experiment design. It includes no administration protocol and makes no repair or wellness claim; catalog material is laboratory research only.

Declared composition and reference identities

Component Declared amount Reference identity (free-form records)
BPC-157 10 mg 15-residue peptide GEPPPGKPADDAGLV; PubChem CID 9941957; CAS 137525-51-0
GHK-Cu 50 mg Copper complex of glycyl-L-histidyl-L-lysine; PubChem prezatide copper CID 71587328; CAS 89030-95-5
TB-500 10 mg N-acetylated heptapeptide Ac-LKKTETQ; PubChem CID 62707662; CAS 885340-08-9
KPV 10 mg H-Lys-Pro-Val-OH tripeptide; PubChem CID 125672; CAS 67727-97-3

The table maps published reference identities, not batch assay results. Counterions (notably acetate for some peptide components), copper stoichiometry, water and residual solvents contribute mass that is not active-moiety mass; the CoA must define the reporting basis for every declared milligram figure.

Component evidence map (preclinical, not blend proof)

BPC-157. A synthetic pentadecapeptide represented in PubChem as sequence GEPPPGKPADDAGLV (CID 9941957). Published orthopaedic research remains overwhelmingly preclinical; a 2025 systematic review noted limited and uncontrolled human reporting, so component studies motivate hypotheses rather than conclusions about this blend (PMID 40756949). Free peptide and acetate salts differ in mass balance and should not be conflated on a CoA.

GHK-Cu. The histidyl-lysyl-glycyl tripeptide coordinates copper; reference complex records list prezatide copper CID 71587328 (PubChem). Historical rat wound-chamber and fibroblast studies connect the complex to extracellular-matrix readouts (PMID 8227353; PMID 3169264). A blend experiment must distinguish GHK-equivalent, complex-equivalent and elemental-copper quantities, and include copper-only controls.

TB-500. Critical naming point: TB-500 as documented in analytical literature is the N-acetylated heptapeptide Ac-LKKTETQ (residues 17–23 of thymosin beta-4), not full-length 43-residue thymosin beta-4 (CID 62707662; Ho et al. 2012, PMID 22962027). Later LC-MS/MS work showed parent-versus-metabolite signals must be measured over time rather than assumed stable (PMID 38382158). Verify the acetyl group and sequence on every CoA; full-length thymosin-beta-4 literature does not transfer automatically.

KPV. Lys-Pro-Val corresponds to the C-terminal tripeptide of alpha-MSH in common nomenclature; PubChem CID 125672 records the free peptide identity (link). Cell and mouse studies examined PepT1 uptake and inflammatory signaling endpoints (Dalmasso et al. 2008, PMID 18061177); a 342 Da small tripeptide can elute early in chromatography and face ionization competition in a four-component mixture, demanding method-specific recovery checks.

Why a blend needs four QC packages, not one

A fit-for-purpose CoA for KLOW should make four separate identity statements and four separate quantitative statements:

1. Identity: LC-HRMS for each analyte; MS/MS or reference comparison for BPC-157 and TB-500 sequences; explicit confirmation of TB-500 N-acetylation.

2. Quantitation: component-specific calibration rather than equal HPLC-area assumptions; detector response factors differ across peptides and the copper complex.

3. Copper: elemental copper result separated from intact GHK-Cu and uncomplexed GHK; stoichiometry stated or at least bounded.

4. Impurities and basis: truncations, TB-500 deacetylation, oxidation, acetate counterions, water and residual solvents; free-peptide versus salt basis labeled for each component.

5. Stability: recovery of all four analytes at the start and end of the experimental interval, since adsorption, copper exchange and proteolysis can change actual exposure.

Chromatographic purity at one wavelength cannot alone establish identity, content, copper chemistry or sterility; those claims require orthogonal evidence.

KLOW versus GLOW: composition matters

The store lists two related but different blends; do not merge them in writing or in the lab:

Dimension KLOW GLOW
Components BPC-157 10 + GHK-Cu 50 + TB-500 10 + KPV 10 mg BPC-157 10 + GHK-Cu 50 + TB-500 10 mg
Declared arithmetic total 80 mg 70 mg
Distinguishing component Adds KPV tripeptide No KPV
Reference pages KLOW blend GLOW blend

Comparative studies should run both blends alongside each single component and a KPV-only arm to attribute any difference to the added tripeptide.

Experimental design checklist

Define the material (lot, forms, bases); separate identity from activity; build a component matrix (each alone, pairwise where relevant, full blend); prespecify an additivity model rather than labeling any larger response “synergy”; match exposure on a defined mass or molar basis; measure intact analytes over time; use cell-free controls for GHK-Cu color and redox interference; normalize to viability and cell count; report null results and exclusions. Standalone component research pages such as the GHK-Cu research reagent provide per-component documentation that supports these controls.

Compliance boundary

KLOW is not a drug, cosmetic or supplement, and no published component study validates this exact four-component mixture for any human or veterinary purpose. Literature references above are preclinical and component-specific. Qualified researchers remain responsible for lawful procurement, institutional review, analytical validation, occupational safety and chemical waste disposal.

Frequently Asked Questions

What is KLOW blend?

A declared four-component research mixture of BPC-157 10 mg, GHK-Cu 50 mg, TB-500 10 mg and KPV 10 mg; it is a mixture, not one molecule.

Is TB-500 the same as thymosin beta-4?

No. TB-500 here is acetylated heptapeptide Ac-LKKTETQ; full-length thymosin beta-4 is a 43-residue protein with different mass and literature context.

Does the CoA need four separate identities?

Yes. Four analytes each require identity evidence, component-specific quantitation, copper reporting for GHK-Cu, and impurity/basis documentation.

What does “synergy” require in a blend study?

A prespecified quantitative model comparing components alone, partial mixtures and the full blend; a bigger response than one component alone is not synergy evidence.

How does KLOW differ from GLOW?

KLOW adds KPV (declared total 80 mg); GLOW contains three components (declared total 70 mg). The pages must be compared by composition, not brand name alone.

Why does copper chemistry matter for GHK-Cu?

Free copper, uncomplexed GHK and the intact complex differ biologically and analytically; stoichiometry must be measured, and copper-only controls are needed.

What stability checks fit a four-component mix?

Measure all four analytes at assay start and end, assess adsorption/degradation/copper exchange in the actual matrix, and validate aliquots and storage conditions.

Is KLOW approved for human use?

No. It is research-only material; component preclinical papers do not establish blend safety, efficacy or a dosing regimen.


View KLOW Blend: KLOW peptide blend catalog listing · compare GLOW peptide blend · lot CoA on request · laboratory research only; not for human or veterinary use.

Related Research Guides

The GHK-Cu compound data file collects the sequence, molecular weight, CAS and the impurity routes worth watching for this compound on one page.

Leave a Reply

Your email address will not be published. Required fields are marked *